HC Wainwright Has Positive Outlook of TNGX FY2026 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities researchers at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Tango Therapeutics in a report released on Monday, October 27th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.41) per share for the year, up from their previous estimate of ($1.44). The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q4 2026 earnings at ($0.37) EPS.

A number of other equities analysts also recently commented on TNGX. Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a research report on Monday. Guggenheim upped their price objective on shares of Tango Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, October 24th. Piper Sandler initiated coverage on shares of Tango Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $11.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Tango Therapeutics Stock Performance

Shares of Tango Therapeutics stock opened at $7.97 on Thursday. The company has a market cap of $886.74 million, a P/E ratio of -5.99 and a beta of 1.67. Tango Therapeutics has a one year low of $1.03 and a one year high of $9.70. The firm has a fifty day moving average of $7.58 and a two-hundred day moving average of $5.37.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35). The firm had revenue of $3.18 million during the quarter, compared to analysts’ expectations of $6.41 million. Tango Therapeutics had a negative net margin of 599.11% and a negative return on equity of 79.72%.

Hedge Funds Weigh In On Tango Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its holdings in Tango Therapeutics by 30.7% during the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after acquiring an additional 1,640 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Tango Therapeutics by 44.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $49,000 after purchasing an additional 2,907 shares in the last quarter. CWM LLC increased its position in Tango Therapeutics by 182.2% during the 2nd quarter. CWM LLC now owns 4,905 shares of the company’s stock worth $25,000 after purchasing an additional 3,167 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in Tango Therapeutics by 78.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock worth $40,000 after purchasing an additional 3,452 shares in the last quarter. Finally, ProShare Advisors LLC grew its holdings in shares of Tango Therapeutics by 30.1% during the second quarter. ProShare Advisors LLC now owns 19,775 shares of the company’s stock worth $101,000 after buying an additional 4,570 shares in the last quarter. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Tango Therapeutics

In other Tango Therapeutics news, major shareholder Rock Ventures Iv L.P. Third sold 477,401 shares of the firm’s stock in a transaction dated Thursday, October 23rd. The shares were sold at an average price of $10.15, for a total transaction of $4,845,620.15. Following the completion of the transaction, the insider directly owned 13,386,574 shares in the company, valued at approximately $135,873,726.10. This trade represents a 3.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 3,472,501 shares of company stock valued at $26,350,320 in the last ninety days. 7.50% of the stock is owned by company insiders.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.